KRAS and neoplasm: Interest in KRAS mutant NSCLC is growing because of the lack of any specific agent available in patients harbouring such molecular alteration, the high incidence in non-squamous NSCLC and the association with smoking history and therefore with tumour mutational burden, one of the most innovative predictive biomarkers to immunotherapy.